Antioxidant Potential of Adiponectin and Full PPAR-γ Agonist in Correcting Streptozotocin-Induced Vascular Abnormality in Spontaneously Hypertensive Rats

Table 3

Plasma triglycerides and lipoprotein (LDL, HDL, and VLDL) level profile of WKY, SHR control, and SHR diabetic treated groups with irbesartan, pioglitazone, adiponectin, and a combination of adiponectin with irbesartan or pioglitazone.

Groups	Lipid profile
	Triglycerides (mg/dL)	Total cholesterol (mg/dL)	HDL (mg/dL)	LDL (mg/dL)
WKY+CNT
SHR+CNT	^!	^!	^!	^!
SHR+STZ
SHR+STZ+Irb	^δ#	^δ#	^δ#	^δ#
SHR+STZ+Pio	^δж	^δж	^δж	^δ
SHR+STZ+Adp	^δ	^δ	^δ	^δ
SHR+STZ+Irb+Adp	^δ	^δ	^δ	^δ
SHR+STZ+Pio+Adp	^δζ	^δζ	^δ	^δ

Notes: the values are presented as the in each group and were analyzed by one-way ANOVA followed by Bonferroni post hoc test. Values with were considered statistically significant during and at the end of treatment. ! indicates significant difference () between the SHR and WKY control groups. indicates significant difference () in comparison to the SHR control group. δ indicates significant difference () of the diabetic Irb, Pio, Adp, Irb+Adp, and Pio+Adp groups in comparison to the SHR diabetic control group. # indicates significant difference () between the diabetic Irb and Adp groups. ж indicates a significant difference () between the diabetic Pio and Adp groups. ζ indicates a significant difference () of the diabetic Adp group in comparison to the diabetic Pio+Adp group at days 21 and 28.